Patients hospitalized with an infective exacerbation of bronchiectasis unrelated to cystic fibrosis: Clinical, physiological and sputum characteristics
- PMID: 28236369
- PMCID: PMC7169079
- DOI: 10.1111/resp.13005
Patients hospitalized with an infective exacerbation of bronchiectasis unrelated to cystic fibrosis: Clinical, physiological and sputum characteristics
Abstract
Background and objective: Bronchiectasis is a growing health burden both globally and in Australasia. Associated with repeated respiratory infections, the disease often results in hospital admission, impaired quality of life, reduced lung function and shortened life expectancy. We describe the local clinical, physiological and sputum characteristics in patients hospitalized with an infective exacerbation of bronchiectasis.
Methods: This study examined the medical records of all 61 adults admitted to a metropolitan Australian hospital with an infective exacerbation of bronchiectasis in a calendar year.
Results: Baseline characteristics include: mean (SD) age of participants was 66 (14) years; 56% were women and 42% were current or ex-smokers. The majority had other coexisting medical conditions, with asthma in 44%, COPD in 59% and both asthma and COPD in 31%. Seventy-two percent were on regular inhaled medication, 23% on cyclical antibiotics and 26% undertook regular respiratory physiotherapy. Bronchodilator reversibility was present in 17% and small airway reversibility in 41%. Sputum demonstrated normal flora in 17%, Pseudomonas aeruginosa in 32%, Haemophilus influenzae in 15% and both organisms in 17%. Mean numbers of exacerbations per year requiring hospitalization was 2.3. Sixty-two percent of subjects had an Index of Relative Socio-Economic Disadvantage in deciles 1-5. Risk factors for exacerbations included a history of asthma or COPD, documented small airway reversibility and presence of P. aeruginosa.
Conclusion: Patients hospitalized with an infective exacerbation of bronchiectasis are predominantly older with co-morbidities and of lower socio-economic status. Presence of P. aeruginosa was a risk factor for repeated exacerbations, as was a history of asthma, COPD or small airway reversibility.
Keywords: Pseudomonas; asthma; bronchiectasis; exacerbation; socio-economic.
© 2017 Asian Pacific Society of Respirology.
Similar articles
-
Relationship between the presence of bronchiectasis and acute exacerbation in Thai COPD patients.Int J Chron Obstruct Pulmon Dis. 2018 Mar 2;13:761-769. doi: 10.2147/COPD.S139776. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 29535516 Free PMC article.
-
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.Lancet Respir Med. 2019 Mar;7(3):213-226. doi: 10.1016/S2213-2600(18)30427-2. Epub 2019 Jan 15. Lancet Respir Med. 2019. PMID: 30658914 Clinical Trial.
-
Respiratory Pathogens at Exacerbation in Chronic Bronchitis With Airway Bacterial Colonisation: A Cohort Study.Clin Respir J. 2024 Aug;18(8):e13811. doi: 10.1111/crj.13811. Clin Respir J. 2024. PMID: 39162176 Free PMC article.
-
The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis.Lancet Respir Med. 2019 Oct;7(10):855-869. doi: 10.1016/S2213-2600(19)30185-7. Epub 2019 Aug 9. Lancet Respir Med. 2019. PMID: 31405826
-
The 'ABC' of respiratory disorders among adult Indigenous people: asthma, bronchiectasis and COPD among Aboriginal Australians - a systematic review.BMJ Open Respir Res. 2023 Jul;10(1):e001738. doi: 10.1136/bmjresp-2023-001738. BMJ Open Respir Res. 2023. PMID: 37451702 Free PMC article.
Cited by
-
Association between pulmonary function and rapid kidney function decline: a longitudinal cohort study from CHARLS.BMJ Open Respir Res. 2024 Feb 23;11(1):e002107. doi: 10.1136/bmjresp-2023-002107. BMJ Open Respir Res. 2024. PMID: 38395458 Free PMC article.
-
Do Patients with Bronchiectasis Have an Increased Risk of Developing Lung Cancer? A Systematic Review.Life (Basel). 2023 Feb 7;13(2):459. doi: 10.3390/life13020459. Life (Basel). 2023. PMID: 36836816 Free PMC article. Review.
-
Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study.Respir Res. 2017 Sep 30;18(1):176. doi: 10.1186/s12931-017-0659-x. Respir Res. 2017. PMID: 28964260 Free PMC article.
-
Factors influencing survival and mortality among adult Aboriginal Australians with bronchiectasis-A 10-year retrospective study.Front Med (Lausanne). 2024 May 7;11:1366037. doi: 10.3389/fmed.2024.1366037. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38774399 Free PMC article.
-
Antimicrobial Resistance in Common Respiratory Pathogens of Chronic Bronchiectasis Patients: A Literature Review.Antibiotics (Basel). 2021 Mar 20;10(3):326. doi: 10.3390/antibiotics10030326. Antibiotics (Basel). 2021. PMID: 33804631 Free PMC article. Review.
References
-
- Chang AB, Bell SC, Torzillo PJ, King PT, Maguire GP, Byrnes CA, Holland AE, O'Mara P, Grimwood K. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med. J. Aust. 2015; 202: 21–3. - PubMed
-
- Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non‐CF Guideline Group . British Thoracic Society guideline for non‐CF bronchiectasis. Thorax 2010; (65 Suppl. 1): i1–58. - PubMed
-
- Lim A, Puah S, Abisheganaden J. Factors associated with mortality in hospitalised patients with bronchiectasis [abstract]. Am. J. Respir. Crit. Care Med. 2014; 189: A6251.
-
- Roberts ME, Lowndes L, Milne DG, Wong CA. Socioeconomic deprivation, readmissions, mortality and acute exacerbations of bronchiectasis. Intern. Med. J. 2012; 42: e129–36. - PubMed
-
- Patel IS, Vlahos I, Wilkinson TM, Lloyd‐Owen SJ, Donaldson GC, Wilks M, Reznek RH, Wedzicha JA. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 170: 400–7. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical